Advertisement
<< Back To Article
More Treatment, Less PrEP Would Slash New HIV Cases by 94%
Write a Comment
2 Comments
Well the question is are we really going to start a fight over allocations to end new HIV transmissions because of lower funding allocations? I hope not. PrEP has been shown in many lab studies to effectively reduce new HIV infections and to bring into the health system person not really destined to go see a doctor before for prevention. Which everyone benefits from. The problem with this study's idea to re-allocate funding to TASP and testing is not a good idea.
Rupi3000
The actual issue is that we have to calculate with $12,599 annual cost for prep. That’s obscene profiteering by pharma companies and others in the ‘value’ chain. You can source Truvada for less than $20 for a 30 pill supply (see cost plus drugs - US manufacturer of generics, they mark up production cost by 15% and sell it for that price) which amounts to $240 per year or about 2% of what you’d pay through the ‘health care’ system.
February 24, 2023